Joel Harris, CEO from Genvax discusses the $6.5 Million funding to Advance saRNA Platform

262

Joel Harris, CEO from Genvax joins us to discuss what this means.

Genvax Technologies, a startup dedicated to bringing advances in self-amplifying mRNA (saRNA) vaccine production to animal health, announced today it has secured $6.5 million in series seed funding. This funding moves the company toward USDA and international regulatory approval of its vaccines in anticipation of any foreign animal disease outbreak in order to increase health and profitability in livestock production.

Genvax Technologies Secures $6.5 Million to Advance saRNA Platform to Deploy Candidate Vaccines against New and Emerging Livestock Diseases Rapidly